Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

Research output: Contribution to journalJournal articleResearchpeer-review

Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.
Original languageEnglish
JournalCurrent Opinion in Investigational Drugs
Issue number4
Pages (from-to)402-13
Number of pages11
Publication statusPublished - 2008

Bibliographical note

Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Humans; Hypoglycemic Agents; Molecular Structure; Patents as Topic; Piperidines; Structure-Activity Relationship; Treatment Outcome; Uracil

ID: 8416764